

Supplementary Figures

Pancreatic cancer regression by Gemcitabine elaidate and ONC201 combination therapy in a syngeneic mouse model

Virender Kumar,¹ Bharti Sethi,¹ Dalton Staller,² Prakash Shrestha¹ and Ram I Mahato^{1,*}

¹Department of Pharmaceutical Sciences University of Nebraska Medical Center, Omaha, NE 68198

²Department of Cellular & Integrative Physiology, University of Nebraska Medical Center, Omaha, NE 68198

This file includes:

Figures: S1 to S5




Figure S1. MTT assay in MIA PaCa-2 cells after 72 h of treatment with L_GEM and ONC201 at different concentrations. A) Cell survival after treatment. B) Combination index curve.




Figure S2. Representative images of MIA PaCa-2 cells in different phages of cell cycle post 24 h treatment with L_GEM and ONC201 at different concentrations, while non-treated cells were used as the control.




Figure S3. Representative pictures showing the percentage of MIA PaCa-2 cells that underwent apoptosis after being exposed to L_GEM and ONC201 at various doses for 24 hours, with untreated cells serving as the control.




Figure S4. Images showing the proportion of ALDH-positive cells in MIA PaCa-2 cells after treatment with L_GEM and ONC201 for 24 hours at varying doses, with untreated cells serving as a control.




Figure S5. Quantitation of density of signals from Western blot analysis for proteins cleaved Caspases 3/8, cleaved PARP1, and DR5.